Poseida Therapeutics Inc. (PSTX) stock prices were up by 1.22% as of the market closing on October 11th, 2021. This brought the price per share up to USD$6.65 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 7.37%, bringing it down to USD$7.14.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
Partnership with Takeda
October 12th, 2021 saw PSTX stock announce having entered into a research and collaboration and exclusive license agreement with Takeda. The collaboration with Takeda Pharmaceutical Company Ltd. will utilize the company’s piggyback, Cas-CLOVER, biodegradable DNA, and RNA nanoparticle delivery technology. In conjunction with other proprietary genetic engineering platforms for the research and development of up to eight gene therapies. The partnership will focus on developing non-viral in vivo gene therapy programs, including the company’s Hemophilia A program.
Details of the Collaboration
The partnership with the global biopharmaceutical leader will complement the company’s innovative platform technologies and robust gene therapy pipeline. The company’s technologies offer highly efficient gene delivery, fully integrated non-viral genome insertion, and ultra-precise site-specific gene editing. The partnering companies hope to develop potential cures for a number of genetic diseases with high unmet need. As per the agreement, the partners will work to initially develop up to six in vivo gene therapy programs that will utilize PSTX stock’s novel technology platforms, as well as certain emerging technologies. these platforms include its piggyBac, Cas-CLOVER, and biodegradable nanoparticle technology. The partnering company has included an option to add two addition programs to the collaboration and will be obligated to provide funding for all the R&D costs of the collaboration program.
PSTC Stock’s Lucrative Collaboration
PSTX stock is set to receive an upfront payment of USD$45 million. If milestones for six programs are achieved, the company can also expect additional payments that have the potential to exceed and aggregate of USD$125 million. The company is also eligible to receive future clinical development, regulatory, and commercial milestone payments. The total potential value of the course of the partnership could reach USD$2.7 billion, should the milestones for all six programs are achieved. Achieving milestones for the additional two programs would bring the potential total up to USD$3.6 billion.
Future Outlook for PSTX Stock
The company is keen to capitalize on the expanded scope of opportunities afford to it as a result of its partnership with Takeda. PSTX stock is keen to facilitate the development of all of the combined programs that are a part of the collaboration. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal effectively. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.
